Russian scientists develop Ebola vaccine

The vaccine will be first tested on animals

Ebola virus
Press Trust of India Moscow
Last Updated : Dec 29 2014 | 5:56 PM IST
Russian researchers have developed a candidate vaccine to protect against the deadly Ebola virus which will soon undergo human clinical trials in Africa.

A group of scientists at the St Petersburg-based Research Institute of Influenza developed the vaccine and its trials are due to complete in Africa in February.

"The candidate vaccine against Ebola created by a group of young scientists of our institute is undergoing tests for genetic stability," said Oleg Kiselev, director of the Research Institute of Influenza.

Also Read

The vaccine will be first tested on animals. The clinical tests involving volunteers will be conducted in Africa, Russian news agency Itar-TASS reported.

All the stages of trials are due to wrap up in February, Kiselev said.

Last week, researchers from the National Institutes of Allergy and Infectious Diseases (NIAID) in the US reported that the first trial of an experimental Ebola vaccine in an African population has shown it is safe for use.

Researchers in China have also developed a vaccine to combat the spread of deadly Ebola virus and will test the drug on humans.

According to the World Health Organisation (WHO), the death toll from the current Ebola outbreak has reached 7,693 and as many as 19,695 have been infected.

Most deaths were reported in the hardest-hit West African countries - Liberia, Sierra Leone and Guinea.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 29 2014 | 5:47 PM IST

Next Story